Selonterra
Selonterra is a pioneering company focused on fighting neurodegeneration by fundamentally transforming therapies for neurodegenerative disorders through harnessing human genetics and gene regulatory networks. Their mission is to address the root causes of neurodegenerative diseases with innovative research, targeted patient approaches, and advanced small molecule programs, particularly in Alzheimer's and Parkinson's diseases.
Industries
Nr. of Employees
small (1-50)
Selonterra
1900 South Norfolk Street, Suite 350, San Mateo, CA 94403-1171, USA
Patents
Use of APOE4 motif-mediated genes for diagnosis and treatment of alzheimer's disease
US-12385093-B2
View Details
Use of APOE4 motif-mediated genes for diagnosis and treatment of alzheimer's disease
US-12385093-B2
View DetailsProducts
Small molecule modulators for Alzheimer's Disease (APOE4)
Developed compounds targeting APOE4-induced gene expression dysfunction and synaptic deficits in Alzheimer's disease.
Small molecule modulators for Parkinson’s Disease (SNCA A53T, LRRK2 G2019S)
Identified drug targets for Parkinson’s disease focusing on SNCA and LRRK2 gene variants.
Therapies for ALS/FTD (C9orf72 Repeat Expansion)
Programs targeting ALS and FTD caused by C9orf72 nucleotide repeat expansions.
Therapies for Alzheimer’s Disease (Familial mutations)
Complementary programs addressing single nucleotide variants in familial Alzheimer's disease.
Lead Optimization and IND-enabling studies
Process of optimizing lead compounds for regulatory studies and potential clinical trials.
Small molecule modulators for Alzheimer's Disease (APOE4)
Developed compounds targeting APOE4-induced gene expression dysfunction and synaptic deficits in Alzheimer's disease.
Small molecule modulators for Parkinson’s Disease (SNCA A53T, LRRK2 G2019S)
Identified drug targets for Parkinson’s disease focusing on SNCA and LRRK2 gene variants.
Therapies for ALS/FTD (C9orf72 Repeat Expansion)
Programs targeting ALS and FTD caused by C9orf72 nucleotide repeat expansions.
Therapies for Alzheimer’s Disease (Familial mutations)
Complementary programs addressing single nucleotide variants in familial Alzheimer's disease.
Lead Optimization and IND-enabling studies
Process of optimizing lead compounds for regulatory studies and potential clinical trials.
Expertise Areas
- Neurodegenerative disease therapeutics
- Human genetics-driven target discovery
- Gene regulatory network analysis
- Small-molecule drug discovery and medicinal chemistry
Key Technologies
- Human genetics analysis
- Gene regulatory network analysis
- Small-molecule medicinal chemistry
- Lead optimization workflows